As discussed in recent extensive reviews of diagnostic biomarkers of DKD [4] and clinical management [5], a growing body of evidence from prospective and cross-sectional studies supports the utility of plasma or urinary protein markers originating from various anatomical sites of origin, such as cystatin C [6,7], copeptin [8], kidney injury molecule-1 (KIM-1) [9,10], neutrophil gelatinase-associated lipocalin (NGAL) [7], TNF receptors, as well as microRNAs. This evidence concerns the gene HAVCR1 and diabetic kidney disease.